Clinical Trials Logo

Retinal Dystrophy clinical trials

View clinical trials related to Retinal Dystrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05902962 Recruiting - Retinal Dystrophy Clinical Trials

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

Platypus
Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

NCT ID: NCT05820100 Completed - Clinical trials for Retinitis Pigmentosa

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

Start date: April 25, 2023
Phase:
Study type: Observational

This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.

NCT ID: NCT05130385 Recruiting - Glaucoma Clinical Trials

High Resolution Optical Coherence Tomography

Start date: November 30, 2021
Phase:
Study type: Observational

Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases

NCT ID: NCT04545736 Recruiting - Clinical trials for Retinal Degeneration

Oral Metformin for Treatment of ABCA4 Retinopathy

Start date: November 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Background: ABCA4 retinopathy is a genetic disease in which the ABCA4 protein is absent or faulty. It can cause waste material to collect in the eye and may cause cells to die. The cell death can lead to vision loss. Researchers want to see if an oral drug called metformin can help. Objective: To see if metformin is safe and possibly helps to slow the rate of ABCA4 retinopathy. Eligibility: People age 12 and older who have ABCA4 retinopathy and have problems with their vision. Design: Participants will be screened under a separate protocol. Participants will have a medical and family history. They will complete a questionnaire about their vision and daily activities. They will have a physical exam. They may have blood drawn through a needle in the arm. Participants will have an eye exam. Their pupils may be dilated with eye drops. Their retina may be photographed. Participants will have a visual field test. They will sit in front of a large dome and press a button when they see a light within the dome. Participants will have an electroretinogram. It examines the function of the retina. They will sit in the dark for 30 minutes. Then their eyes will be numbed with eye drops. They will wear contact lenses that can sense signals from the retinas. They will watch flashing lights. Participants will have optical coherence tomography. This non-invasive procedure makes pictures of the retina. Participants will have fundus autofluorescence. A bright blue light will be shone into their eye. Participants will take metformin by mouth for 24 months. Participants will have study visits every 6 months. Participation will last for at least 36 months....